Record number of cancer drugs launched in 2018, says report
The IQVIA report also explores health system barriers hindering the realisation of the benefits of those therapies and drug candidates.
Read More
Author: Anna Smith
FDA breakthrough therapy designation granted for Bayer’s Aliqopa
The decision was primarily based on follow-up data from the pivotal Phase II study CHRONOS-1.
Read More
Univar’s Cufence leads latest CHMP decisions
The committee recommended four treatments including two generic medicines.
Read More
Sosei get $2.5m for QVM149 MAA
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
Read More
Positive late stage rheumatoid arthritis trial results for Abbvie
Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
